
— ImmunoGen Inc. (NASDAQ: IMGN) reported its fourth-quarter 2019 earnings of $0.03 per share vs $0.05 per share loss expected.
— Revenue jumped threefold to $44.8 million, versus $29.3 million expected. The results were helped by higher license fees and lower operating expenses.
— For fiscal 2020, company expects revenues between $60 million and $65 million. Operating expenses are projected to be between $165 million and $170 million.
— IMGN shares shot up 5.4% immediately following the announcement.
Listen to on-demand earnings calls and hear how management responds to analysts’ questions
Most Popular
Key metrics from Biogen’s (BIIB) Q4 2024 earnings results
Biogen Inc. (NASDAQ: BIIB) reported its fourth quarter 2024 earnings results today. Total revenue increased 3% year-over-year to $2.5 billion. Net income attributable to Biogen Inc. was $266.8 million,
Important takeaways from Coca-Cola’s (KO) Q4 2024 earnings
The Coca-Cola Company (NYSE: KO) has wrapped up fiscal 2024 on an upbeat note, reporting stronger-than-expected results for the final quarter of the year. Encouraged by the growth in sales
Walt Disney (DIS): A look at the performance of the streaming business in 1Q25
Shares of The Walt Disney Company (NYSE: DIS) dropped 1% on Tuesday. The stock has gained 6% over the past three months. The company delivered top and bottom line growth
Comments
Comments are closed.